Fundraising Fox

Novapep

San Diego, US · 1 known investors

Novapep is an Australian-US biotech company developing G10, a polypeptide agonist that mimics activated protein C signaling to reduce inflammation. The company focuses on peptide-based therapeutics for inflammatory and infectious diseases.

BiotechMedical Devices

Founders & leadership

JG
John GriffinCo-founder
LM
Laurent MosnierCo-founder
CJ
Chris JacksonCo-founder
JH
Jay HennockCEO & Executive Director
KP
Kent PryorExecutive Director

Board

RA
Rob AntulovChairman

Investors · 1

Sydney AngelsSydney · $10K – $50K

In the news

Australia's biggest week in biotech officially begins at AusBioInvest - Biotechbiotechdispatch.com.au · Oct 2024Novapep's Pioneering Approach to Treating Inflammatory Bowel Diseases - Wholesale Investorwholesaleinvestor.com · Oct 2024Heterobivalent Peptide Agonists Comprising Covalently Linked Protease Activated Receptor 1 and Protease Activated Receptor 3 Peptides Mimic the Cytoprotective Cell Signaling Activities of Activated Protein C - ScienceDirectsciencedirect.com · Nov 2023

Frequently asked questions

What does Novapep do?
Novapep is an Australian-US biotech company developing G10, a polypeptide agonist that mimics activated protein C signaling to reduce inflammation. The company focuses on peptide-based therapeutics for inflammatory and infectious diseases.
Who founded Novapep?
Novapep was founded by John Griffin, Laurent Mosnier, Chris Jackson.
Who are Novapep's investors?
Novapep's investors include Sydney Angels.
Where is Novapep headquartered?
Novapep is headquartered in San Diego, US.